Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27309824 | 0.98 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Phenethylamine SCHEMBL27612223 | 0.79 | CDK2 (0.45) | ALDH1A1KDM4ECDK2RXFP1POLA1 | |
| SCHEMBL7663294 | 0.78 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL3578267 | 0.78 | ALDH1A1 (0.53) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL29452971 | 0.77 | ALDH1A1 (0.63) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL5748057 | 0.76 | ALDH1A1 (0.61) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL31058752 | 0.75 | KDM4E (0.50) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL357005 | 0.74 | KDM4E (1.00) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL3896 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL408916 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739788-A1 | COMPOSITION COMPRISING MODIFIED DNA IDENTIFIER SEQUENCES FOR DNA MODIFICATION SCREENING | ETH Zurich (CH) | 2026-05-13 | — | — | EP | claimed |
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4514954-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| EP-4514953-A1 | NOVEL CRISPR-CAS12F SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| CN-119421948-A | Novel CRISPR-Cas12f system and application thereof | 辉大(上海)生物科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119331309-A | Methyl purine ferulic acid aromatized water magnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2025012092-A1 | COMPOSITION COMPRISING MODIFIED DNA IDENTIFIER SEQUENCES FOR DNA MODIFICATION SCREENING | ETH ZURICH (CH) | 2025-01-16 | — | — | WO | claimed |
| EP-4488381-A1 | MODIFIED DNA IDENTIFIER SEQUENCES FOR DNA MODIFICATION SCREENING | ETH Zurich (CH) | 2025-01-08 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-118749029-A | Novel CRISPR-Cas12i system and application thereof | 辉大(上海)生物科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| EP-1499628-A4 | RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-COA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1515985-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF MUTANT P53 | El-Gewely, Mohammed Raafat (NO) | 2005-03-23 | — | — | EP | claimed |
| EP-1499628-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-COA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| EP-1499631-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003072600-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF TARGET PROTEINS AND PEPTIDES THAT RESTORE THE FUNCTION OF MUTANT P53 | GARDNER, REBECCA, KATHERINE (GB) | 2003-09-04 | — | — | WO | claimed |
| WO-2003070885-A2 | SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| WO-2003070197-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030134819-A1 | Recombinant bacterial cells for delivery of PNP to tumor cells | SOUTHERN RESEARCH INSTITUTE | 2003-07-17 | — | — | US | claimed |
| CN-1172417-A | Feed for fishes and shellfishes | PROD DEV RES INST (JP) | 1998-02-04 | — | — | CN | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | RBM12, PRR12, HM13 | ALDH1A1 4821/4885KDM4E 4769/4885CDK2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.